It showed non-MDSC tumor-resident myeloid populations produced CCL5 in response to CD40 activation, but not in response to immune checkpoint blockade, and CCL5-recruitment of CD4+ T cells mediated treatment efficacy. This evidence concerns the gene CD40 and neoplasm.